FDA Adverse Event Malfunction Summary report: N

LEADCARE II BLOOD LEAD TEST SYSTEM

MDR report key: 8027073 · Received October 31, 2018

Report

Report Number
1218996-2018-00030
Event Type
Malfunction
Date Received
October 31, 2018
Date of Event
December 19, 2012
Report Date
October 31, 2018
Manufacturer
MAGELLAN DIAGNOSTICS, INC.
Product Code
DOF
UDI-DI
00850355006017
PMA / PMN Number
K052549
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MO, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

A USER FACILITY CALLED MAGELLAN'S PRODUCT SUPPORT ON TO REPORT TEST FAILED ERROR MESSAGES ON THEIR LEADCARE BLOOD LEAD ANALYZER. THE ANALYZER WAS RETURNED TO MAGELLAN FOR EVALUATION. DURING INVESTIGATIVE TESTING, MAGELLAN OBSERVED REPEATED FAILED EXTERNAL CONTROL TESTS. ERROR MESSAGES WERE CONFIRMED WHEN REVIEWING THE ANALYZER LOG FILES. NO REPORTED HARM OR INJURIES OCCURRED AS A RESULT OF THIS ISSUE. CORROSION WAS NOTED ON SENSOR PINS. CORROSION OF THE SENSOR PINS OCCURS WHEN THERE IS OVEREXPOSURE OF THE ANALYZER PINS TO THE ASSAY'S ACIDIC TREATMENT REAGENT. THIS OCCURS WHEN USED TEST SENSORS ARE NOT REMOVED IMMEDIATELY AFTER TESTING (PER INSTRUMENT INSTRUCTIONS) OR WHEN TOO MUCH SAMPLE IS ADDED TO THE TEST SENSOR. PERIODIC TESTING WITH BLOOD LEAD QC CONTROLS IS USED TO MONITOR ANALYZER PERFORMANCE. MAGELLAN PROVIDED THE CUSTOMER WITH A NEW INSTRUMENT, ADDITIONAL TRAINING, SENT THEM NOTIFICATIONS. NO FURTHER ISSUES OF THIS NATURE HAVE BEEN SHOWN FOR THIS CUSTOMER. NOTE: LATE FILING IS PART OF MAGELLAN DIAGNOSTICS, INC. RESPONSE TO FDA'S 483 ISSUED ON (B)(4) 2017. (B)(4). CUSTOMER COMPLAINT: (B)(4).

Description of Event or Problem · 1

A USER FACILITY CALLED MAGELLAN'S PRODUCT SUPPORT ON TO REPORT TEST FAILED ERROR MESSAGES ON THEIR LEADCARE BLOOD LEAD ANALYZER.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
862806 LEADCARE II BLOOD LEAD TEST SYSTEM LEADCARE II ANALYZER DOF MAGELLAN DIAGNOSTICS, INC. 00850355006017

Patients

Seq Age Sex Outcome Treatment
1